STRIBILD

This brand name is authorized in Austria, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug STRIBILD contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 4GDQ854U53 - ELVITEGRAVIR
 

Elvitegravir, is a type of antiviral agent called an ‘integrase inhibitor’. It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV. When the enzyme is blocked, the virus cannot reproduce normally, slowing down the spread of infection.

 
Read more about Elvitegravir
2
UNII LW2E03M5PG - COBICISTAT
 

Cobicistat is a mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.

 
Read more about Cobicistat
3
UNII G70B4ETF4S - EMTRICITABINE
 

Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ.

 
Read more about Emtricitabine
4
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE
 

Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.

 
Read more about Tenofovir disoproxil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J05AR09 J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
CA Health Products and Food Branch 02397137
EE Ravimiamet 1616149, 1616150
ES Centro de información online de medicamentos de la AEMPS 113830001
FI Lääkealan turvallisuus- ja kehittämiskeskus 168038
FR Base de données publique des médicaments 65768058
GB Medicines & Healthcare Products Regulatory Agency 231638
IL מִשְׂרַד הַבְּרִיאוּת 7426
IT Agenzia del Farmaco 042815011, 042815023
LT Valstybinė vaistų kontrolės tarnyba 1070337, 1070338
NL Z-Index G-Standaard, PRK 146587
PL Rejestru Produktów Leczniczych 100156785
SG Health Sciences Authority 14835P
TR İlaç ve Tıbbi Cihaz Kurumu 8698760090083, 8698760090090
US FDA, National Drug Code 61958-1201

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.